Key result
PCSK9 inhibitors require a justified pricing strategy to appropriately reflect their clinical and economic value.
Key points are not available for this paper at this time.
See Article by Ko et al .
No takes yet. Share an insight, caveat, or question.
Khurram Nasir (2018) studied this question. PCSK9 inhibitors require a justified pricing strategy to appropriately reflect their clinical and economic value.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: